Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Indole-3-carbinol prevents colitis and associated microbial dysbiosis in an IL-22–dependent manner
Philip B. Busbee, … , Mitzi Nagarkatti, Prakash S. Nagarkatti
Philip B. Busbee, … , Mitzi Nagarkatti, Prakash S. Nagarkatti
Published January 16, 2020
Citation Information: JCI Insight. 2020;5(1):e127551. https://doi.org/10.1172/jci.insight.127551.
View: Text | PDF
Research Article Immunology Inflammation

Indole-3-carbinol prevents colitis and associated microbial dysbiosis in an IL-22–dependent manner

  • Text
  • PDF
Abstract

Colitis, an inflammatory bowel disease, is caused by a variety of factors, but luminal microbiota are thought to play crucial roles in disease development and progression. Indole is produced by gut microbiota and is believed to protect the colon from inflammatory damage. In the current study, we investigated whether indole-3-carbinol (I3C), a naturally occurring plant product found in numerous cruciferous vegetables, can prevent colitis-associated microbial dysbiosis and attempted to identify the mechanisms. Treatment with I3C led to repressed colonic inflammation and prevention of microbial dysbiosis caused by colitis, increasing a subset of gram-positive bacteria known to produce butyrate. I3C was shown to increase production of butyrate, and when mice with colitis were treated with butyrate, there was reduced colonic inflammation accompanied by suppression of Th17 and induction of Tregs, protection of the mucus layer, and upregulation in Pparg expression. Additionally, IL-22 was increased only after I3C but not butyrate administration, and neutralization of IL-22 prevented the beneficial effects of I3C against colitis, as well as blocked I3C-mediated dysbiosis and butyrate induction. This study suggests that I3C attenuates colitis primarily through induction of IL-22, which leads to modulation of gut microbiota that promote antiinflammatory butyrate.

Authors

Philip B. Busbee, Lorenzo Menzel, Haider Rasheed Alrafas, Nicholas Dopkins, William Becker, Kathryn Miranda, Chaunbing Tang, Saurabh Chatterjee, Udai P. Singh, Mitzi Nagarkatti, Prakash S. Nagarkatti

×

Full Text PDF | Download (11.68 MB)


Copyright © 2022 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts